Clinical trials: Idiopathic Pulmonary Fibrosis, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Idiopathic Pulmonary Fibrosis
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are sudden and severe worsening episodes that can be life-threatening. Currently, no treatment has been proven to clearly improve outcomes during these events.
- Trial name
- MERCURION-IPF (NCT07299695)
- Testing
- Intravenous immunoglobulin (IVIG), Usual treatment
- Where
- Greece
- Volunteers
- 196 people
- Sponsor
- Argyrios Tzouvelekis
Idiopathic Pulmonary Fibrosis
Study of ORJ-001 for the Treatment of IPF
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by…
- Trial name
- NCT07869147
- Testing
- ORJ-001
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Oorja Bio, Inc.
Idiopathic Pulmonary Fibrosis (IPF)
Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
At present, the diagnosis of IPF is still difficult and it cannot be completely cured. Treatment is still aimed at improving symptoms and delaying the decline of lung function.
- Trial name
- IPF II (NCT07131150)
- Testing
- SC01009 injection
- Where
- 22 sites in China
- Volunteers
- 66 people
- Sponsor
- Ruijin Hospital
Idiopathic Pulmonary Fibrosis (IPF)
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy
This study is a prospective, single-arm, dose-escalation exploratory clinical trial to investigate the safety, tolerability and preliminary efficacy of REGEND007 stem cell preparation administered by intravenous infusion in the…
- Trial name
- NCT07359963
- Testing
- REGEND007 Cell Therapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Regend Therapeutics
Adjustment Disorder
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to…
- Trial name
- NCT07002034
- Testing
- RE104 for Injection
- Where
- 32 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reunion Neuroscience Inc
Pulmonary Fibrosis, Lung Fibrosis
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
- Conditions
- Pulmonary Fibrosis, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, FAP
- Trial name
- FAPIPET (NCT06189820)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Erasme University Hospital
Idiopathic Pulmonary Fibrosis(IPF)
CAR-DC for End-Stage IPF
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal interstitial lung disease characterized by irreversible scarring, leading to respiratory failure.
- Trial name
- NCT07329959
- Testing
- Leukapheresis, CAR-DC
- Volunteers
- 8 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Idiopathic Pulmonary Fibrosis (IPF)
Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis
This is a multicenter, Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT07447102
- Testing
- BC006
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Idiopathic Pulmonary Fibrosis
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for…
- Trial name
- STRIVE II (NCT07674745)
- Testing
- Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Alabama at Birmingham
Interstitial Lung Disease, Pulmonary Fibrosis
Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis
The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using [68Ga]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced…
- Trial name
- NCT07572383
- Testing
- [68Ga]CBP8, Gadoterate Meglumine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Peter Caravan
Idiopathic Pulmonary Fibrosis
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- ZAPPHIRE (NCT07516951)
- Testing
- CHF10067
- Where
- 19 sites in United States, North Macedonia and 2 more
- Volunteers
- 240 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven to be effective in AI-FPI.
- Trial name
- EXAFIP2 (NCT05674994)
- Testing
- Methylprednisone/Prednisone
- Where
- 29 sites in France
- Volunteers
- 110 people
- Sponsor
- Fondation Hôpital Saint-Joseph